| __timestamp | Neurocrine Biosciences, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 5903000 |
| Thursday, January 1, 2015 | 33800000 | 2762000 |
| Friday, January 1, 2016 | 35900000 | 1114000 |
| Sunday, January 1, 2017 | 1254000 | 25573000 |
| Monday, January 1, 2018 | 4889000 | 6000000 |
| Tuesday, January 1, 2019 | 7400000 | 38845000 |
| Wednesday, January 1, 2020 | 10100000 | 50523000 |
| Friday, January 1, 2021 | 14300000 | 75463000 |
| Saturday, January 1, 2022 | 23200000 | 105767000 |
| Sunday, January 1, 2023 | 39700000 | 167512000 |
| Monday, January 1, 2024 | 34000000 |
Cracking the code
In the competitive landscape of biotechnology, understanding cost structures is crucial. Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Neurocrine's cost of revenue started at approximately $14 million in 2014, peaking at nearly $40 million by 2023, reflecting a growth of over 180%. In contrast, Xenon Pharmaceuticals began with a modest $5.9 million, skyrocketing to $167 million in 2023, marking an astonishing increase of over 2700%.
While both companies have seen significant growth, Xenon's cost of revenue has outpaced Neurocrine's, indicating a more aggressive expansion or higher operational costs. This divergence highlights the varying strategies and market conditions faced by these biotech firms. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these companies.
Cost of Revenue Comparison: Biogen Inc. vs Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
Walgreens Boots Alliance, Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.